Key Highlights
- $27.5 million Series A funding closed by iVEAcare, led by Vensana Capital alongside Treo Ventures and others.
- Todd Kerkow appointed as President and CEO, bringing extensive industry experience.
- Focus on developing innovative neuromodulation technology for medical use.
Source: PR Newswire
Notable Quotes
- “This Series A financing enables iVEAcare to deliver innovative neuromodulation therapy to patients and clinicians.” – Todd Kerkow, President and CEO at iVEAcare
- “We are excited to see the third spin-off from NuXcel attract such seasoned investors.” – Tracy Pappas, General Partner at Treo Ventures and Mudit Jain, Co-founder & Chairman at iVEAcare
- “Neuromodulation is one of the most exciting frontiers in medicine. We are enthusiastic to partner with iVEAcare’s experienced team.” – Amrinder Singh, Partner at Vensana Capital and Kirk Nielsen, Managing Partner at Vensana Capital
SoHC's Take
The substantial investment in iVEAcare underscores the growing importance and potential of neuromodulation technologies in the medical field. With a strong leadership team headlined by Todd Kerkow and backed by a consortium of experienced investors, iVEAcare is poised to push the boundaries of what’s possible in medical therapy. This strategic influx of capital will likely catalyze significant advancements in treatment options, highlighting an exciting phase of growth and innovation for the company and its partners.
